In two recent articles, our Chief Scientific Officer shared his vision of the first thymus-empowered allogeneic CAR ProTcell therapies to address the pitfalls currently hampering a highly promising sector. Olivier Negre was interviewed by CGT Insights in August, more specifically on the personnalization issues. He also signed an article in the European Pharmaceutical Review that was published on September 4th.
Both contents are freely accessible:
European Pharmaceutical Review: How breakthrough CAR-T cancer therapies could be made more widely accessible